Geneoscopy
Company

Last deal

$105M

Amount

Series B

Stage

16.11.2021

Date

3

all rounds

$112.9M

Total amount

date founded

Financing round

General

About Company
Geneoscopy developed a non-invasive diagnostic test for colorectal cancer using stool samples.

Industry

Sector :

Subsector :

founded date

01.01.2015

Number of employees

Company Type

For Profit

Last funding type

Series B

IPO status

Private

Description

Geneoscopy aims to replace the unpleasant colonoscopy screening by extracting human RNA transcripts from stool samples to detect changes in gene expression. This innovative methodology provides a platform to detect, prevent, and guide treatment for gastrointestinal disease. Geneoscopy's lead diagnostic, which uses stool-derived eukaryotic RNA, has been recognized by the FDA for its ability to reduce morbidity associated with colorectal cancer. The company's research also extends to inflammatory bowel disease diagnostics in collaboration with biopharmaceutical companies and academic research institutions.
Contacts

Contact Email

Phone number

Social url

Similar Companies
1000
Devyser

Devyser

Devyser develops and sells diagnostic kits used for complex DNA testing in oncology, hereditary diseases and transplantation.

Sector

Medical Equipment and Services

Subsector

Medical Services

Keywords

Biotechnology, Health Care, Health Diagnostics

Location

Hägersten-Liljeholmen, Stockholm, Sweden
GenePath Dx

GenePath Dx

GenePath Dx is a diagnostics company that provides advanced molecular diagnostic techniques to the medical and healthcare communities.

Sector

Medical Equipment and Services

Subsector

Medical Services

Location

Pune, Maharashtra, India

total rounds

1
Novomics

Novomics

Novomics provides gene-based molecular examination for post-stomach cancer surgery prognosis.

Sector

Medical Equipment and Services

Subsector

Medical Services

Location

Yeongdeungpo-gu, Seoul, South Korea

total rounds

3

total raised

$1.26M
Promis Diagnostics

Promis Diagnostics

Promis Diagnostics develops non-invasive diagnostics for colon cancer screening.

Sector

Medical Equipment and Services

Subsector

Medical Services

Location

Pasadena, CA, USA

Financials

Funding Rounds
4
3

Number of Funding Rounds

$112.9M

Money Raised

Their latest funding was raised on 16.11.2021. Their latest investor NT Investments. Their latest round Series B

Date 
Funding Round 
Investors 
Money Raised 
Lead 

NT Investments

NT Investments is an investment firm.

Sector

Investment Banking and Brokerage Services

Subsector

Asset Managers and Custodians

count Of Investments

1

NT Asset

NT Asset

count Of Investments

3

Lightchain

Lightchain is a non-profit organization specializing in IT software and the internet.

Sector

Software and Computer Services

Subsector

Software

Keywords

Software, Information Technology

count Of Investments

10
Cultivation Capital

Cultivation Capital

Cultivation Capital is a venture capital firm that invests in early-stage technology startups.

Sector

Investment Banking and Brokerage Services

Subsector

Asset Managers and Custodians

Location

St. Louis, MO, USA

count Of Investments

206

count Of Exists

26

NT Asset

NT Asset

count Of Investments

3
Co-Investors
Investors
11
4

Number of lead investors

11

Number of investors

Investor 
Lead 
Round 
Partners 
Yes
Series B
No
Venture - Series Unknown
No
Series A

NT Investments

NT Investments is an investment firm.

Sector

Investment Banking and Brokerage Services

Subsector

Asset Managers and Custodians

count Of Investments

1
Missouri Technology Corporation

Missouri Technology Corporation

Missouri Technology Corporation is a venture capital firm that promotes entrepreneurship and fosters the growth of high-tech companies.

Sector

General Industrials

Subsector

Diversified Industrials

Location

Jefferson City, MO, USA

count Of Investments

104

count Of Exists

9

Rodger Riney

count Of Investments

1

People

Founders
3
Yiming Kang
Yiming Kang

Yiming Kang

organization founded

1

Yiming Kang

Erica Barnell
Erica Barnell

Erica Barnell

Erica graduated from Cornell University in 2013 with a dual degree in Biological Sciences and Applied Economics & Management. She started her career as a research technician at the Donald Danforth Plant Science Center in St. Louis, where she was engineering the staple food crop in Africa to be more nutritious. She then began working at the Washington University School of Medicine to develop a noninvasive diagnostic test to evaluate children in Africa with Environmental Enteropathy Disease. Currently, she is in her fourth year of the MD/PhD Program at the Washington University School of Medicine where her PhD concentration is in Genetics and Genomics.

current job

Geneoscopy
Geneoscopy

organization founded

1

Erica Barnell

Andrew Barnell
Andrew Barnell

Andrew Barnell

Andrew began his career as a financial analyst in J.P. Morgan’s healthcare investment banking group, working primarily on M&A and capital markets transactions in the biotech, medical devices, and life science tools sectors. Subsequently, he worked as an associate at Lindsay Goldberg, a middle-market private equity firm focused on providing long-term growth capital to family owned businesses. As an undergraduate at Cornell University, Andrew studied Applied Economics & Management with a specialization in finance. He also received an MBA from The Wharton School, with majors in Health Care Management and Entrepreneurial Management.

current job

Geneoscopy
Geneoscopy

organization founded

1

Andrew Barnell

Employee Profiles
5
Haytham Gareer

Haytham Gareer

Chief Medical Officer

Eric Duncavage

Eric Duncavage

Chief Medical Officer

Beekey Cheung

Director of engineering

Erica Barnell

Erica Barnell

Co-founder, Chief Science Officer

Andrew Barnell

Andrew Barnell

Co-Founder and Chief Executive Officer

Activity

Recent News
18
News Timeline

The graph reveals the ratio (%) of positive news articles in a chosen time range

week